Real-world data is being reported for a breast cancer test that combines immunohistochemistry and ai-based prognostics. The test appears to involve image analysis that can predict cancer biomarkers and survival outcomes, potentially for both breast and colorectal cancer. Research on the use of artificial intelligence in analyzing breast cancer immunohistochemistry is also being discussed, including its application in classifying HER2 status.